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Chapter II 
Obesity and Hyperandrogenism 
Amit M. Deokar, Shawn J. Smith, 
Amanda J. Goodwin and Hatim A. Omar * 
Division of Adolescent Medicine, Department of Pediatrics, University of Kentucky, 
Lexington, Kentucky, United States of America 
Abstract 
This chapter has a two-fold objective. One, it addresses the associatiOn of 
hyperandrogenism and obesity and the complex metabolic derangements that are part of 
the problem. Clinical management of these co-morbidities is challenging and complex. 
Second, this article will aid health care providers with the key features to an early 
diagnosis and intervention to decrease the morbidities in the short as well as long term. 
Method: Systematic review of articles and information on the topic of interest that were 
published in the last 15 years. Conclusion: Obesity and hyperandrogenism are integral 
.·parts of Metabolic Syndrome/Polycystic Ovarian Syndrome (PCOS)/Hyperandrogenism, 
Insulin resistance, and Acanthosis Nigricans (HAIR-AN). With the childhood obesity 
epidemic, the metabolic syndrome and the associated abnormalities are routinely seen in 
clinical practice and these have a tremendous economic burden on the society and the 
quality of life. 
Introduction 
Obesity in children and adolescents has increased at an alarming rate in the last two u~'""'~"" 
Over the years, researchers have acquired a better understanding about the 
of obesity in metabolic syndrome (MS, previously lmown as metabolic 
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Patients with MS have various metabolic abnormalities that can include abnonnal glucose 
and insulin ratio, insulin resistance, high blood pressure, altered lipid profile, pro-thrombotic 
and pro-inflammatory state. Teenagers with .MS are predisposed to long term morbidities, 
such as early coronary mte1y .disease, hepatic; steatosis, type 2 diabetes, and stroke [1] . 
~:!~::~:;~~gt~;sa~~~~ ~;7ot~~~;ei~~t. ~0r&ger~as a~ . ~o percent chance of continuing to be 
Approximately 17 perce~t of children ag7g 2~ 19 years are considered overweight based 
on a survey by}'l"ational Health and Nutritiqn Examination Survey of 2003-2004 [3]. As 
noted earlier, the rate of obesityha~ double(iin ·~doles.ce11ts,who are in the 12-19 year age 
group [4]. The prevalem:e .of obese and overweight children may be different depending on 
the gender···· artd~Illn~city. ······Fo~ e~a111ple, · !he ·otesitY .1'(\tes i·~rf . }}}ghet iiJ.l African Americans, 
Hispanic Americans, males, and those living in the southem :states [2]. The definition of 
obesity varies in adolescents when compared to adults due to different proportion of body fat 
in boys and girls at different ages [5]. Body Mass Index (BMI) is a reliable tool to assess 
obesity, because it is easy to obtain and correlates well with the bqqyfat [6]. Any adolescent 
with a BMI of 30 kg/m2 or 95th percentile for gender and age falls in the overweight 
category. They are considered at risk of being overweight if their BMI is between 85th and= 
95th percentile. In the US, the economic burden of direct and indirect healthcare cost due to 
obesity and co-morbidities is estimated to be well over$ 117 billion annually. As the obesity 
rates have doubled and tripled respectively in children and adolescents, so have the health 
care costs [7]. This impacts the healthcare burden directly. 
Obesity and hyperandrogenism (HA) are strongly associated in patients who have been 
diagnosed to have polycystic ovarian syndrome (PCOS)/HA/MS. This article addresses their 
relationship with one another and specific management options. A subset of (PCOS) includes 
hyperandrogenism, insulin resistance and acanthosis nigricans, abbreviated as HAIR-AN 
[8,9]. Historically PCOS was described based on findings of multiple cysts in the ovaries, 
irregular or no menstrual periods, and hirsuitism. However, absence of ovarian cysts does not 
rule out this syndrome [10]. Women with high androgenlevels have assoCiated HAIR-AN 
features in about 5-10 percent of cases [11]. The onset of PCOS/HAIR-AN may occurs in 
adolescent years and the diagnosis is likely to be delayed until early adulthood [8,9]. 
Pathophysiology 
As PCOS/HAIR-AN is being studied more over the last two decades, different theories have 
been proposed to explain the features of the syndrome, including obesity. The primary 
problem in HA appears to be due to an altered hypothalamo-pituatary-ovarian axis. The 
anovulation and thus abnormal or absence of menstrual periods is from a persistent 
leutenizing hormone (LH) surge and its high concentration in the blood. There is also an 
increased GnRH surge as the negative feedback fi-om estrogen and progesterone is ineffective 
due to relative hypothalamic insensitivity. The LH surge results in increased production of 
androgens. The level of follicle stimulating hormone (FSH) is less when compared to the LH 
resulting in decreased enzymatic (aromatase) conversion of androgen to estrogen and thus 
anovulation. 
Obesity and 
Another key association of HA is hyperinsulinsm. This is 
resistance, which can result in a hyperglycemic state. The level of sex' .,A,.,"''"., 
globulin (SHBG) is decreased due to the high insulin levels and consequently there 
in the free testosterone level [8]. Insulin also increases the androgen productio\1. by 
stimulating the theca cells [12]. Both hyperinsulinism and HA predispose an ind ' 
have an athrogenic lipid profile. Total cholesterol, triglycerides (TG) levels are also 
Increased activity of the enzyme lipase affects the cholesterol metabolism and could result in 
a decreased level of the high density lipoprotein-cholesterol (HDL-C) [13]. Another 
postulated mechanism for HAIR-AN is a genetic mutation of the insulin receptor (tyrosine 
kinase domain) [9]. 
Effects ofHA can be multi-fold. Even though increased androgen production in women 
is associated with obesity, one study in 2002 by Gapstur et al [14] in obese men have found 
to have lower testosterone and dehydroepiandroterone sulfate (DHEAS) levels. High 
androgen levels in children and adolescents are linked to precocious puberty, accelerated 
bone growth, height, features of PCOS, and are more commonly seen in obese subjects 
compared to non-obese. In pre-pubertal obese children the level of DHEAS is often elevated 
[14]. 
Recently, researchers have looked at the effects of proteins like adiponectin, resistin, 
leptin, and TNF -a on the fat metabolism, peripheral insulin resistance, and energy 
expenditure [15]. Resistin is produced by the mature visceral and subcutaneous adipocytes 
and influences insulin sensitivity. Adiponectin and leptin, also secreted fi-om the adipocytes, 
have similar roles [16]. A recently published study by Shin et al [17] suggested obesity as an 
inflammatory process due to findings of increased levels of C-reactive protein (CRP) and 
TNF found in obese children. The adiponectin level was found to be much lower 
concentration in these children. Retinol Biding Protein 4 (RBP4) is present in omental and 
subcutaneous fat and is expressed more in women with PCOS [18]. The high levels of 
androgen and features of metabolic syndrome have shown to normalize in post-menarche 
obese adolescents after weight reduction [19]. 
Diagnostic Criteria 
A standard list of the diagnostic criteria for MS in children and adolescents is still lacking. 
However, a modified diagnostic criteria for children using the NCEP criteria and data from 
the National Health and Nutrition Examination Survey (NHANES, 1988-94) is widely used. 
The National Cholesterol Education Program (NCEP) and the Adult Treatment Panel III 
(ATP III) include at least 3 of 5 of the following criteria for the diagnosis of MS in 
[1,2,20,21]. 
• Abnmmal lipid panel: Hypertriglyceridemia (> 150 mg/dl) and 
(<40mg/dl in males and <50 in females). 
• High fasting glucose level. Hyperglycemic state is defined as 
100 mg/dl or more. 
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Elevated ·blood .pr.f!ssm·~, syst()li£, qia~t()li<:, ()r both using reference ranges. From 
example, .. blood pres~we 0f )-13,5/~.5 ~'11lw-rg; . i~ . 9011.~idered abnormai. 
Increased waist ci.J.·cl!IJ1fer~~l9e/apqg~~·~l. . g;i~ll· J3MI . is fairly reliable in assessing 
obesity in children... > .> i ·i<' ic . isi iii > 
High inslllit1resistance ( cdterio~ it1pl~j!dr~.nJx .\ 
The World Health Organizatiol1(\}'H("))£ri~~ri~ . required elevated insulin or glucose 
level (> 11 Omg/dl) in a.ddit ... ~.· on t·.o·.•·••• .. ·.··a···· .. • .. ·.·t··.•.·.·.·•.·.•.•.··.· •. l .. ·.·.•.· .•.·.·.e· ... · ..• · ..•• ·.a···.· .. ·.·.•.·.·.·.··s.·.· ...•.· .... •.·.·.t .... •.•.· .·.· . ·.·.· .. ·.·· .. ···t···· .. • ..• .··.w . ·.·.•·.•.·.·.·.·.·.•.•.·.·.o.·.· .. ·.·•.·.· •  •. ·····.···o.• .. ·.··· ... ·•· .. ·.••.•.f.·.·.·.··.·.·. the following: [2] Abdominal obesity • • .· ·••••· ••• ·.•. < < 
waist size >94 em or waist to hip s~t~()!()~)-9;1 
Triglycerides > 150 mg/dl . orl!l)J, <::;~.$p.ig(gl· 
Blood pressure > 140/90rm1ll!g . 
HAIR-AN is a clinical diagnosis and includes t p~l~~1h~,in addition to criteria mentioned 
above (9]: 
i":·:: 
a) Acne, hirsuitism,, ~~~pora1 . bl,l}~'pg, ;i¢m(.)i(.)ffi¢galy, and deepening of 
(suggestive ofhighandrogep.Jf!Yf!D· 
VOICe 
b) Acrochordons (skin tags), a.cat1W()~i~t1}$1"lcf~~~(llsll(llly found on the neck, axillae, 
and back). These are suggystiye ()fii).§\lHII.Xf!Si§t<lP.Pe and altered hmmonallevels. 
<;r!(·t;<:~ 
Sugg~~~~~:;:WQrkup 
Anthropometric measurement, vital,' , ~ ~~~c~JJceinplete history and physical exam 
(including genital) is reconunended. ~~et.eil~~ f~~ly,past medical, and medication history 
should also be documented. Laboratgt1'/4~~~ <:11,af:i l}l<lY be useful includes, fasting levels of 
insulin, glucose (complete metabolic Pel1elit~ ~~§es~ Ji;er . and renal function) , lipid panel, 
glucose/insulin ratio, HgAlc, and AMcqnisgll~;e~.Qral glucose tolerance test (2 hour) is 
also recommended to document hyperglyc~~t sta.te. One test that has high sensitivity and 
specificity is the euglycemic hyperills11li.t1errgp plamp. This may be impractical in a clinical 
setting due to the time consumin~a~g potl"lpl~.xeamr·e of the test (9]. A thorough endocrine 
evaluation should include thyroid >:flll:i<:tipt1 tests, serum prolactin, DHEA-S, am 17-
hydroxyprogesterone (17-0HP), sHBqle)'f!l,aed free and total testosterone. IGF-1 level 
may be helpful in a suspected growt11h()J.1POp.eproducmg tumor [22]. 
· In order to establish the diagnosispf~(:JQS, .the presence of multiple ovarian cysts is not 
necessary. Likewise, an abdomillal/peJyiq .@tr~sound detection of multiple ovarian cysts does 
not confitm that diagnosis either. Q<;:c(lSi()riaUy a computed tomography (CT) or an MRI of 
the abdomen/pelvis may be necessary in situations where there are progressive signs of 
hyperandrogenism [22]. 
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Outcome 
HAIR-AN subset) in children can lead to 
Ju1IJll'-·'"'-·U short and long term medical problems. This exhaustive list includes 
to the following [6]: 
Distorted body image and perception 
Low self-esteem and depression 
Acne 
Obesity associated problems like snoring, obstructive sleep apnea, disordered sleep, 
gastro esophageal reflux disease (GERD), gall stones, joint pain, exercise 
intolerance, features of diabetes, coronary artery disease, and skin changes, etc. 
Amenonhea (predisposing to subsequent inadequate bone mineralization) and 
possibly infe1tility. 
Treatment Options 
timeframe for the diagnosis of metabolic syndrome/HAIR-AN to the outcome of the 
c('l.a,tm~nt varies from patient to patient and can be often protracted. A multidisciplinary 
is often required to address the metabolic as well as the psychological stressors 
with this syndrome. reatment should be geared toward specific metabolic 
u .... u .... .., as well [6,9,23]. It is important for the healthcare provider to be aware of the 
that teenagers may have when it relates to cosmetic appearance. At a psychological 
... .., .• ,..,""P1Hv1.1la1 stage where bodily appearance plays an important role in a teenager 's life, 
, ... , ~",,,.related problems such as acanthosis nigricans, acne, and hirsuitism may be quite 
~ ..... ---~·eo [22]. This can affect their self-esteem directly. Health care providers should have a 
.,, •·u"'""'"1u for refening these teenagers to counseling services. 
Mf11vu,"'u compliance can play a big role with this approach, it is considered one of the most 
and successful mode of treatment in obese patients, who also have HA [22). Weight 
dramatically improve the ovarian function and decrease the levels of androgens [24]. 
dietary changes such as caloric restriction of carbohydrates or fat with increased 
intake ]).ave been previously studied. There is no sufficient data available if restrictio11, 
is better than that of fat intake. It is therefore prudent to use the 
,-···-·u ... or nutritionist who can work with obese/overweight individuals. 
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treatment may include a 
androgens, insulin-sensitizing 
and complementary and 
•u•••u·u·"~"H·'u'·'"" J approach, psychological 
Biguanide: Metformin a pregnancy category 
B drug, has (DM). From a glycemic stand 
point, Metfonnin interten::s JiVitb tb< l1t¢p,;*>P:Yi.e ••rQJttQ.I~b~mcirilll respiratory oxidative process 
and decreases not a complete blockade of 
gluconeogenesis. It in tissues such as the skeletal 
muscles, by ·· activating on the insulin receptors and 
enhancing the glucose is also on the adipocytes. It 
also acts against the gl Metformin is particularly useful in 
obesity associated with HA. Due to there is a consequent decrease 
in the free and total estradiol level [25]. This has a 
beneficial effect on ovulation, 
As obesity is strongly ... .,.,v...,, ..... .,.u ""Vt!f'I-''W~·'YY"f~~,uH~· morbidity and mortality, metformin 
has an added benefit of being shown to decrease the free fatty 
lipoprotein cholesterol 
C). It also lowers the platelet agJ~re,g~ti9n 1:\r\g. ;~q~t~slon, 
plasminogen inhibitor 1 and von 
[26]. It can induce vascular uo•a"-'~'f~'l.l '~l.l~'\~0"!"'~'-' ~~gt 
. It may also help lower the total 
(VLDL-C), low density 
lipoprotein cholesterol (HDL-
with an addition of drosperinone 
,.,.,..,...~,....., .,,...abdominal fat [27]. 
gastrointestinal symptoms such as 
nausea, flatulence and uu•Lau''-'"· ""'''"' .Lna.v LJ" ' '"'u'-'"~''u by taking it with food. Treatment may 
be started with a single daily a lowest possible dose. It may then be 
increased to a twice daily dose. re,CbJ:nplertde:d to go over the maximum dosage of 
2.25 grams/day [25]. One must potential toxicity from metfromin that 
includes lactic acidosis in rare si ua••v"·"· 1\,lf.>tf'n·rrn; ... is fairly safe for the mother and baby 
during pregnancy and lactation [28]. 
Thiazolidinediones: Rosiglitazone is an insulin sensitizing agent, whose action on the 
peroxisome proliferator-activated receptor (PP AR ) on the adipocytes improves glucose 
transport into the cell by increasing the adiponectin secretion [29]. In studies done earlier on 
overweight women with PCOS, there was a decrease in the insulin resistance and return of 
ovulation as indicated by regular menses. The SHBG level also shows an increase that helps 
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ovulation. Some of the side effects include weight gain 
Ll">'-''"IJ'J'u'" individuals [30]. 
ulation of the Hormonal/ Androgen Imbalance and Use of Oral 
aceptives 
bitih control pills (BCP's) are the cornerstone in the treatment of HA. Their 
,,,10..,u,uu,~u• of action includes the following: 
Increase the SHBG production and level: This allows a reduction of free 
testosterone. 
Suppress LH: Decreases androgen production from the ovaries. 
Anti-minerelocmiicoid activity: Certain progestins such as Drosperinone have low 
androgenic activity and are generally preferred in HA. The brand name 
contraceptives Yasmin® and Otiho-Tri-Cyclen® contain Drosperinone. 
effects of combination BCP's include normalization of menses and a decrease in acne 
hirsuitism [22]. In addition to the above, other phannacologic agents have been tried in 
states are cyproterone acetate, :finastreride, glucocorticoid, such as prednisone (patients 
late onset congential adrenal hyperplasia (CAH) having PCOS features), and 
Surgery: A decrease in obesity-related morbidity has been well documented in 
that have undergone Roux-en-Y gastric bypass surgery. Although this is an 
procedure that has been evaluated mostly in morbidly obese adults, the guidelines 
conservative for the adolescent population. Morbidly obese teenagers, who have 
the non-surgical approach may be considered for a gastric bypass surgery. Other 
" ,..,., ..... awuu" in addition to the above includes a BMI of 40 kg/m2 or more, physical and 
"'u''"'"'-'""" co morbidities from obesity [31]. Bariatric surgery intended to result in weight 
can positively impact obesity, PCOS, and reverse anovulation. The risks from obesity 
pregnancy in morbidly obese teens is also decreased by the procedure [31]. A 1 to 2 
post operatively for becoming pregnant is usually recommended. As there can be 
complications from this surgical procedure, careful multidisciplinary evaluation for 
.,....., , .. ...,~--·for surgery is needed. 
plementary and Alternative Medicine 
approaches in the treatment of PCOS have been 
of side effects from the traditional medical and surgical tre:atn1en:t, J·esc~ar,b!J.~~!.'s, / 
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looked at the benefits pfaq4pu:qctur~, l:lj:):<tclitionaLfonn oLChinese medicine. Acupuncture 
has been shown to in lowering of the increased 
sympathetic ton~ the technique of 
acupuncture c(ln ol and LH levels [32]. 
As a result, its 
endogenous systems can 
altemative medicine such as nuJlnt:•up<ii!l:Y> 
have been tried to treat obesity in 
not vety convincing [33]. 
neuro-endocrinal 
Other fonns of 
PHJL11-"'"u'"u•"• and hypnotherapy 
The CDC (Center for Disease ofNutrition and Physical 
Activity (DNPA) and the health established the Nutrition and 
Physical Activity Program to Pr~~velif<oti'esiit\Ji·''aiil:ti !)tf[gr i cltron· Diseases (NPAO) since 
1999 using the social ecological are encouraged to contact 
their individual health departments where available. 
Metabolic syndrome, 
abnormalities that have a great 
The diagnosis is often late and 
problems. The following kyy 
of HAIMS/PCOS and appropriate 
integral part of complex metabolic 
general well-being of an individual. 
ec<mcnnJIC burden from obesity related 
provider with the timely diagnosis 
• Healthcare provider childhood and adolescence. 
• Utilizing diagnostic gitG~~ag '~·~~~~~r+~~M~L§~~ diagnosis of PCOS/HA/MS. One may 
refer to the NCEP, diagnostic criteria. 
• A complete history, family, past, and medications. 
• Complete physical diagnosis of HAIR-AN is clinical. 
• Laboratmy and list includes fasting insulin, glucose 
(complete liver and renal function), lipid panel, 
glucose/insulin level. Oral glucose tolerance test (2 
hour) , thyroid function prolactin, DHEA-S, am 17-hydroxyprogesterone 
(17-0HP), SHBG level, and total testosterone, IGF-1 level are also 
recommended. 
• Management that inclgdes meifical, . surgical, lifestyle modification techniques, and 
appropriate referr~l~ )8 pther sub-specialty providers for addressing associated co 
morbidities. Keepi:qg ip miHci that some patients may desire to utilize altemative and 
complimentary medicine options as well. 
Obesity and Hyperandrogenism 
Multidisciplinary approach that includes, the primary care 
social worker, nutritionist, and counselor/psychologist. 
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